首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

2023943

CRISPR技術市場預測—全球分析（按產品、技術類型、應用、最終用戶和地區分類）—2034年

CRISPR Technology Market Forecasts to 2034 - Global Analysis By Offering, By Technology Type, Application, End User, and By Geography

出版日期: 2026年04月17日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

全球 CRISPR 技術市場預計到 2026 年將達到 42 億美元，並在預測期內以 15.5% 的複合年成長率成長，到 2034 年達到 135 億美元。

CRISPR（叢集規律間隔短回文重複序列）技術是一種突破性的基因編輯工具，能夠對任何生物體的DNA序列進行精確修飾。這項創新平台在許多領域有著廣泛的應用，包括治療方法研發、農業生物技術、工業微生物學以及診斷技術創新。市場涵蓋了種類繁多的產品，例如修飾的Cas酶、專用試劑盒和試劑、引導RNA分子以及全面的CRISPR文庫，此外還包括細胞株修飾、gRNA設計和篩檢檢驗等專業服務。隨著研究機構和生物製藥公司擴大將CRISPR技術應用於功能基因組學和治療藥物發現，該市場正持續快速成長。

增加基因組研究和精準醫療的投資

全球基因組學和個人化醫療領域的資金投入正爆炸性成長，直接推動了CRISPR技術在學術界和商業實驗室中的應用。北美、歐洲和亞洲各國政府紛紛推出大規模舉措，投入數十億美元以揭示疾病背後的遺傳因素並開發標靶治療方法。製藥公司也擴大將CRISPR技術整合到藥物研發流程中，用於標靶檢驗、疾病建模和細胞療法開發。隨著「統一治療方法」向「個人化療法」的轉變日益受到認可，對精準基因編輯工具的需求也持續成長。創業投資對Start-UpsCRISPR技術的新創公司的投資也在加速，為該技術的完善和臨床應用提供支援。

脫靶效應與安全性問題

標靶基因組區域的非預期改變仍是限制CRISPR技術臨床應用的一大挑戰。即使是先進的CRISPR系統也可能在非目標位點引入突變，從而激活癌基因或損害必需基因的功能。監管機構要求對所有候選療法進行全面的脫靶分析，這顯著延長了研發週期並增加了成本。一些備受矚目的研究報告稱，CRISPR編輯後出現了意想不到的基因組重排，這引發了投資者和臨床醫生對安全性的擔憂。在檢測方法改進和遞送系統更加特異性之前，這些擔憂將繼續限制治療應用，尤其是在體內編輯方法方面。

下一代 CRISPR 系統超越了 Cas9。

諸如Cas12、Cas13、鹼基編輯和先導編輯等新型CRISPR平台，憑藉其卓越的特異性和增強的功能，正在不斷擴展技術工具箱。 Cas12能夠以更簡單的嚮導RNA設計實現多重編輯，而Cas13則針對RNA而非DNA，為不涉及永久性基因組改變的瞬時治療應用鋪平了道路。鹼基編輯能夠實現單核苷酸替換而不造成雙鏈，從而顯著降低脫靶風險。先導編輯能夠以最小的產品差異實現精確的插入和刪除。這些創新正在吸引大量研究資金，並形成新的智慧財產權框架。開發自身下一代系統的公司有望透過贏得追求性能優勢的早期採用者群體，獲得巨大的市場佔有率。

複雜的智慧財產權格局與專利糾紛

圍繞CRISPR基礎專利的持續法律糾紛給尋求將該技術商業化的商業開發商和研究機構帶來了不確定性。博德研究所和加州大學之間就CRISPR/Cas9發明權的爭議導致不同司法管轄區重疊的許可要求。企業必須應對分散的專利組合，並可能為單一商業產品向多個方支付專利費。這種複雜性增加了交易成本，阻礙了小規模Start-Ups的建立，並可能延遲產品上市。由於關鍵專利的保護期尚未到期，限制性的授權條件將在可預見的未來繼續影響市場准入和獲利能力。

新冠疫情的影響：

新冠疫情對CRISPR技術市場產生了雙重影響：一方面，它擾亂了非必要研究；另一方面，它加速了CRISPR技術在診斷和治療領域的應用。實驗室關閉暫時延緩了與SARS-CoV-2無直接關聯的學術研究和早期研究計畫。然而，對快速準確檢測的迫切需求推動了基於CRISPR的診斷平台（例如SHERLOCK和DETECTR）的開發，這些平台都獲得了緊急使用授權。此外，疫情導致的資金分配調整優先考慮了疫苗研發和抗病毒研究，其中一些研究將CRISPR技術應用於宿主因子篩檢。這次危機展現了CRISPR技術在基礎研究之外的效用，驗證了即時分子診斷的概念驗證，並加速了監管機構對基於CRISPR產品的理解。

在預測期內，該產品細分市場預計將佔據最大的市場佔有率。

預計在預測期內，該產品細分市場將佔據最大的市場佔有率，這主要得益於科學研究機構在 CRISPR 實驗中對耗材的持續需求。含有各種 Cas 蛋白的酵素、純化試劑盒、最佳化試劑和預先設計的嚮導 RNA 文庫是任何基因編輯工作流程中必不可少的材料。學術實驗室、受託研究機構和製藥公司需要不斷補充這些材料，從而為供應商提供穩定且可預測的收入來源。一體化 CRISPR 試劑盒的日益普及降低了新研究人員的進入門檻，並擴大了基本客群。隨著應用領域從基礎發現擴展到臨床前檢驗，最終到達臨床生產，產品出貨量也隨之成長，進一步鞏固了該細分市場的主導地位。

在預測期內，主剪輯產業預計將呈現最高的複合年成長率。

在預測期內，先導編輯領域預計將呈現最高的成長率，這反映了該技術相比傳統CRISPR方法具有更高的精確性和多功能性。先導編輯無需雙鏈或供體DNA模板即可在目標位點進行插入、缺失和任意鹼基替換，從而顯著降低了脫靶風險。這項特性克服了第一代CRISPR/Cas9技術的許多局限性，使得先導編輯成為安全性至關重要的治療應用領域中極具吸引力的選擇。領先的生物技術公司已建立了專門的先導編輯項目，用於治療鐮狀細胞貧血症、囊腫纖維化和戴-薩克斯病等遺傳性疾病。隨著最佳化工作的不斷推進以及編輯效率和遞送方法的持續改進，預計在整個預測期內，先導編輯技術的應用將迅速成長。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這得歸功於生物技術研究中心的集中分佈、美國國立衛生研究院 (NIH) 的大量政府資助，以及 Editas Medicine、Interior Therapeutics 和 Caribou Biosciences 等領先的 CRISPR 公司的存在。該地區健全的智慧財產權環境和高效的治療藥物開發監管流程，為該技術的商業化創造了有利條件。博德研究所和加州大學等學術機構持續引領 CRISPR 技術的發展，並在北美研究領域中保持領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於各國政府對基因組研究的大力投資以及生物技術基礎設施的快速發展。中國已成為CRISPR領域的領先國家，發表了數千篇論文並開展了大量臨床試驗，這得益於「中國精準醫療計畫」等國家級舉措的支持。日本、韓國和新加坡也正在建立基因組研究所並制定法規結構，以促進CRISPR研究。該地區低廉的人事費用和營運成本使其成為提供CRISPR服務的受託研究機構的理想市場。此外，基因編輯技術在農業作物領域的應用日益廣泛，並根據當地情況進行調整，這也加速了該技術的普及。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要企業進行SWOT分析（最多3家公司）
區域分類
- 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第10章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第11章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第12章：公司簡介

CRISPR Therapeutics AG
Editas Medicine Inc.
Intellia Therapeutics Inc.
Beam Therapeutics Inc.
Caribou Biosciences Inc.
Sangamo Therapeutics Inc.
Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Agilent Technologies Inc.
Horizon Discovery Group plc
New England Biolabs Inc.
GenScript Biotech Corporation
Lonza Group AG
Takara Bio Inc.

簡介目錄圖表

Product Code: SMRC35155

According to Stratistics MRC, the Global CRISPR Technology Market is accounted for $4.2 billion in 2026 and is expected to reach $13.5 billion by 2034 growing at a CAGR of 15.5% during the forecast period. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is a revolutionary gene-editing tool that enables precise modification of DNA sequences across living organisms. This transformative platform has applications spanning therapeutic development, agricultural biotechnology, industrial microbiology, and diagnostic innovation. The market encompasses a diverse range of products including engineered Cas enzymes, specialized kits and reagents, guide RNA molecules, and comprehensive CRISPR libraries, alongside professional services such as cell line engineering, gRNA design, and screening validation. As research institutions and biopharmaceutical companies increasingly adopt CRISPR for functional genomics and therapeutic discovery, the market continues its rapid expansion trajectory.

Market Dynamics:

Driver:

Rising investment in genomic research and precision medicine

Global funding for genomics and personalized therapeutics has surged dramatically, directly fueling CRISPR adoption across academic and commercial laboratories. Governments in North America, Europe, and Asia have launched large-scale genomic initiatives, allocating billions toward understanding genetic drivers of disease and developing targeted interventions. Pharmaceutical companies are increasingly integrating CRISPR into their drug discovery pipelines for target validation, disease modeling, and cell therapy development. The growing recognition that one-size-fits-all treatments are giving way to patient-specific approaches creates sustained demand for precise editing tools. Venture capital investment in CRISPR-focused startups has also accelerated, supporting technology refinement and clinical translation.

Restraint:

Off-target effects and safety concerns

Unintended modifications at genomic sites similar to the intended target remain a significant challenge limiting clinical adoption of CRISPR technologies. Even advanced CRISPR systems can introduce mutations in non-target locations, potentially activating oncogenes or disrupting essential gene functions. Regulatory agencies require exhaustive off-target analysis for any therapeutic candidate, substantially extending development timelines and increasing costs. High-profile studies reporting unexpected genomic rearrangements following CRISPR editing have raised safety questions among investors and clinicians. Until detection methods improve and delivery systems become more specific, these concerns will continue constraining therapeutic applications, particularly for in vivo editing approaches.

Opportunity:

Emergence of next-generation CRISPR systems beyond Cas9

New CRISPR platforms including Cas12, Cas13, base editing, and prime editing are expanding the technological toolbox with superior specificity and expanded functionality. Cas12 enables multiplexed editing with simpler guide RNA designs, while Cas13 targets RNA rather than DNA, opening transient therapeutic applications without permanent genomic changes. Base editing allows single-nucleotide conversions without creating double-strand breaks, dramatically reducing off-target risks. Prime editing offers precise insertions and deletions with minimal byproducts. These innovations are attracting substantial research funding and creating new intellectual property landscapes. Companies developing proprietary next-generation systems are positioned to capture significant market share as early adopters seek performance advantages.

Threat:

Complex intellectual property landscape and patent disputes

Ongoing legal battles over foundational CRISPR patents create uncertainty for commercial developers and research institutions seeking to productize discoveries. The conflicting claims between the Broad Institute and University of California over CRISPR/Cas9 invention rights have resulted in overlapping licensing requirements across different jurisdictions. Companies must navigate fragmented patent portfolios, potentially paying royalties to multiple parties for a single commercial product. This complexity increases transaction costs, discourages small startup formation, and can delay product launches. The expiration timelines of key patents remain distant, meaning restrictive licensing terms will continue affecting market accessibility and profit margins for the foreseeable future.

Covid-19 Impact:

The COVID-19 pandemic had a dual effect on the CRISPR technology market, disrupting non-essential research while accelerating diagnostic and therapeutic applications. Laboratory shutdowns temporarily delayed academic and early-stage research projects not directly related to SARS-CoV-2. However, the urgent need for rapid, accurate testing drove development of CRISPR-based diagnostic platforms such as SHERLOCK and DETECTR, which received emergency use authorizations. Additionally, pandemic-related funding shifts prioritized vaccine development and antiviral research, some of which incorporated CRISPR screening for host factors. The crisis demonstrated CRISPR's utility beyond basic research, establishing proof-of-concept for point-of-care molecular diagnostics and accelerating regulatory familiarity with CRISPR-based products.

The Products segment is expected to be the largest during the forecast period

The Products segment is expected to account for the largest market share during the forecast period, driven by the recurring consumables nature of CRISPR experiments in research settings. Enzymes including various Cas proteins, purification kits, optimized reagents, and pre-designed guide RNA libraries represent the essential inputs for every gene-editing workflow. Academic laboratories, contract research organizations, and pharmaceutical companies require continuous replenishment of these materials, creating stable, predictable revenue streams for suppliers. The increasing availability of all-in-one CRISPR kits has lowered entry barriers for new researchers, expanding the customer base. As applications scale from basic discovery to preclinical validation and ultimately clinical manufacturing, product volumes increase correspondingly, cementing this segment's market dominance.

The Prime Editing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Prime Editing segment is predicted to witness the highest growth rate, reflecting the technology's superior precision and versatility compared to earlier CRISPR methods. Prime editing enables targeted insertions, deletions, and all possible base-to-base conversions without requiring double-strand breaks or donor DNA templates, substantially reducing off-target risks. This capability addresses critical limitations of first-generation CRISPR/Cas9, making prime editing particularly attractive for therapeutic applications where safety is paramount. Major biotechnology companies have established dedicated prime editing programs for genetic disorders including sickle cell disease, cystic fibrosis, and Tay-Sachs. As optimization continues to improve editing efficiency and delivery methods, prime editing adoption is expected to accelerate rapidly throughout the forecast period.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by concentrated biotechnology research hubs, substantial government funding through the National Institutes of Health, and the presence of leading CRISPR companies including Editas Medicine, Intellia Therapeutics, and Caribou Biosciences. The region's robust intellectual property environment and efficient regulatory pathways for therapeutic development create favorable conditions for technology commercialization. Academic institutions such as the Broad Institute and University of California continue pioneering CRISPR advancements, maintaining North America's research leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by aggressive government investments in genomic research and rapidly expanding biotechnology infrastructure. China has emerged as a CRISPR powerhouse, with thousands of publications and numerous clinical trials, supported by national initiatives such as the China Precision Medicine Plan. Japan, South Korea, and Singapore have similarly established genomics institutes and regulatory frameworks facilitating CRISPR research. Lower labor and operational costs make the region attractive for contract research organizations offering CRISPR services. Additionally, increasing agricultural applications of gene editing in crops tailored to local conditions are accelerating adoption.

Key players in the market

Some of the key players in CRISPR Technology Market include CRISPR Therapeutics AG, Editas Medicine Inc., Intellia Therapeutics Inc., Beam Therapeutics Inc., Caribou Biosciences Inc., Sangamo Therapeutics Inc., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Horizon Discovery Group plc, New England Biolabs Inc., GenScript Biotech Corporation, Lonza Group AG, and Takara Bio Inc.

Key Developments:

In February 2026, Beam announced a new liver-targeted program, BEAM-304, for Phenylketonuria (PKU). This program uses base editing to directly correct genetic mutations, with an IND filing planned for later this year.

In February 2026, Intellia announced that the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for ATTR amyloidosis with polyneuropathy. The company resumed patient enrollment for this pivotal study of nexiguran ziclumeran (nex-z).

In December 2025, CRISPR Therapeutics announced the expansion of its oncology pipeline, initiating a Phase 1/2 trial for its next-generation, CRISPR-edited allogeneic CAR-T cell therapy, CTX112, targeting B-cell malignancies with enhanced potency and durability.

Offerings Covered:

Products
Services

Technology Types Covered:

CRISPR/Cas9
CRISPR/Cas12
CRISPR/Cas13
Base Editing
Prime Editing
Other CRISPR Technologies

Applications Covered:

Biomedical Applications
Agricultural Applications
Industrial Applications
Other Applications

End Users Covered:

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations (CROs)
Other End Users

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global CRISPR Technology Market, By Offering

5.1 Products
- 5.1.1 Enzymes (Cas Proteins)
- 5.1.2 Kits & Reagents
- 5.1.3 Guide RNA (gRNA)
- 5.1.4 CRISPR Libraries
- 5.1.5 Other Products
5.2 Services
- 5.2.1 Cell Line Engineering
- 5.2.2 gRNA Design & Synthesis
- 5.2.3 Screening & Validation
- 5.2.4 Custom CRISPR Services
- 5.2.5 Other Services

6 Global CRISPR Technology Market, By Technology Type

6.1 CRISPR/Cas9
6.2 CRISPR/Cas12
6.3 CRISPR/Cas13
6.4 Base Editing
6.5 Prime Editing
6.6 Other CRISPR Technologies

7 Global CRISPR Technology Market, By Application

7.1 Biomedical Applications
- 7.1.1 Drug Discovery & Development
- 7.1.2 Gene Therapy
- 7.1.3 Functional Genomics
- 7.1.4 Disease Modeling
7.2 Agricultural Applications
- 7.2.1 Crop Improvement
- 7.2.2 Livestock Engineering
7.3 Industrial Applications
- 7.3.1 Biofuel Production
- 7.3.2 Enzyme Engineering
- 7.3.3 Synthetic Biology
7.4 Other Applications

8 Global CRISPR Technology Market, By End User

8.1 Pharmaceutical & Biotechnology Companies
8.2 Academic & Research Institutes
8.3 Contract Research Organizations (CROs)
8.4 Other End Users

9 Global CRISPR Technology Market, By Geography

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 United Kingdom
- 9.2.2 Germany
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Netherlands
- 9.2.7 Belgium
- 9.2.8 Sweden
- 9.2.9 Switzerland
- 9.2.10 Poland
- 9.2.11 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Indonesia
- 9.3.7 Thailand
- 9.3.8 Malaysia
- 9.3.9 Singapore
- 9.3.10 Vietnam
- 9.3.11 Rest of Asia Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Colombia
- 9.4.4 Chile
- 9.4.5 Peru
- 9.4.6 Rest of South America
9.5 Rest of the World (RoW)
- 9.5.1 Middle East
  - 9.5.1.1 Saudi Arabia
  - 9.5.1.2 United Arab Emirates
  - 9.5.1.3 Qatar
  - 9.5.1.4 Israel
  - 9.5.1.5 Rest of Middle East
- 9.5.2 Africa
  - 9.5.2.1 South Africa
  - 9.5.2.2 Egypt
  - 9.5.2.3 Morocco
  - 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles

12.1 CRISPR Therapeutics AG
12.2 Editas Medicine Inc.
12.3 Intellia Therapeutics Inc.
12.4 Beam Therapeutics Inc.
12.5 Caribou Biosciences Inc.
12.6 Sangamo Therapeutics Inc.
12.7 Thermo Fisher Scientific Inc.
12.8 Merck KGaA
12.9 Danaher Corporation
12.10 Agilent Technologies Inc.
12.11 Horizon Discovery Group plc
12.12 New England Biolabs Inc.
12.13 GenScript Biotech Corporation
12.14 Lonza Group AG
12.15 Takara Bio Inc.

簡介目錄圖表

List of Tables

Table 1 Global CRISPR Technology Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global CRISPR Technology Market Outlook, By Offering (2023-2034) ($MN)
Table 3 Global CRISPR Technology Market Outlook, By Products (2023-2034) ($MN)
Table 4 Global CRISPR Technology Market Outlook, By Enzymes (Cas Proteins) (2023-2034) ($MN)
Table 5 Global CRISPR Technology Market Outlook, By Kits & Reagents (2023-2034) ($MN)
Table 6 Global CRISPR Technology Market Outlook, By Guide RNA (gRNA) (2023-2034) ($MN)
Table 7 Global CRISPR Technology Market Outlook, By CRISPR Libraries (2023-2034) ($MN)
Table 8 Global CRISPR Technology Market Outlook, By Other Products (2023-2034) ($MN)
Table 9 Global CRISPR Technology Market Outlook, By Services (2023-2034) ($MN)
Table 10 Global CRISPR Technology Market Outlook, By Cell Line Engineering (2023-2034) ($MN)
Table 11 Global CRISPR Technology Market Outlook, By gRNA Design & Synthesis (2023-2034) ($MN)
Table 12 Global CRISPR Technology Market Outlook, By Screening & Validation (2023-2034) ($MN)
Table 13 Global CRISPR Technology Market Outlook, By Custom CRISPR Services (2023-2034) ($MN)
Table 14 Global CRISPR Technology Market Outlook, By Other Services (2023-2034) ($MN)
Table 15 Global CRISPR Technology Market Outlook, By Technology Type (2023-2034) ($MN)
Table 16 Global CRISPR Technology Market Outlook, By CRISPR/Cas9 (2023-2034) ($MN)
Table 17 Global CRISPR Technology Market Outlook, By CRISPR/Cas12 (2023-2034) ($MN)
Table 18 Global CRISPR Technology Market Outlook, By CRISPR/Cas13 (2023-2034) ($MN)
Table 19 Global CRISPR Technology Market Outlook, By Base Editing (2023-2034) ($MN)
Table 20 Global CRISPR Technology Market Outlook, By Prime Editing (2023-2034) ($MN)
Table 21 Global CRISPR Technology Market Outlook, By Other CRISPR Technologies (2023-2034) ($MN)
Table 22 Global CRISPR Technology Market Outlook, By Application (2023-2034) ($MN)
Table 23 Global CRISPR Technology Market Outlook, By Biomedical Applications (2023-2034) ($MN)
Table 24 Global CRISPR Technology Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
Table 25 Global CRISPR Technology Market Outlook, By Gene Therapy (2023-2034) ($MN)
Table 26 Global CRISPR Technology Market Outlook, By Functional Genomics (2023-2034) ($MN)
Table 27 Global CRISPR Technology Market Outlook, By Disease Modeling (2023-2034) ($MN)
Table 28 Global CRISPR Technology Market Outlook, By Agricultural Applications (2023-2034) ($MN)
Table 29 Global CRISPR Technology Market Outlook, By Crop Improvement (2023-2034) ($MN)
Table 30 Global CRISPR Technology Market Outlook, By Livestock Engineering (2023-2034) ($MN)
Table 31 Global CRISPR Technology Market Outlook, By Industrial Applications (2023-2034) ($MN)
Table 32 Global CRISPR Technology Market Outlook, By Biofuel Production (2023-2034) ($MN)
Table 33 Global CRISPR Technology Market Outlook, By Enzyme Engineering (2023-2034) ($MN)
Table 34 Global CRISPR Technology Market Outlook, By Synthetic Biology (2023-2034) ($MN)
Table 35 Global CRISPR Technology Market Outlook, By Other Applications (2023-2034) ($MN)
Table 36 Global CRISPR Technology Market Outlook, By End User (2023-2034) ($MN)
Table 37 Global CRISPR Technology Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
Table 38 Global CRISPR Technology Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
Table 39 Global CRISPR Technology Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
Table 40 Global CRISPR Technology Market Outlook, By Other End Users (2023-2034) ($MN)